A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 146 participants.
Also called NCT05936151
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 146 participants
- Sponsor
- Registry
-
NCT05936151
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Italy, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT05936151. Randomized; double masking; primary purpose treatment. Start 2023-07-20 (actual); primary completion 2025-10-01 (actual). Results posted on 2026-11-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
- Condition
- Overweight or Obesity
- Condition
- CKD (chronic kidney disease)
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Retatrutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct05936151- Content hash
69505d3ae5763a6478f80c5c017fd1adbd4d28531fc3cf5dee964f3eecf83a54